FDA Approves Requip
FDA Approves Requip for Parkinson’s Disease
Requip is a non-ergoline dopamine agonist indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.Posted: September 1997
Related articles
- U.S. FDA Approves Requip XL, the First and Only Oral Once-DailyNon-Ergot Dopamine Agonist for Parkinson's Disease - June 16, 2008
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
